Recombinant Mouse Siglec-G Fc Chimera Protein, CF

In a functional ELISA. Recombinant Mouse Siglec-G Fc Chimera (Catalog # 10103-SL) binds to biotinylated 6'-Sialylactose-PAA.

2 μg/lane of Recombinant Mouse Siglec-G Fc Chimera(Catalog # 10103-SL) was resolved with SDS-PAGE under reducing (R) andnon-reducing (NR) conditions and visualized by Coomassie®Blue staining, showing bands at 102-114 kDa and 205- 230 kDa, respectively.

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse Siglec-G Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA.

  Recombinant Mouse Siglec-G Fc Chimera (Catalog # 10103-SL) binds to biotinylated 6'-Sialylactose-PAA.

• Source: Mouse myeloma cell line, NS0-derived mouse Siglec-G protein
  

  Mouse Siglec-G (Met19-Lys543) Accession # Q80ZE3.1	IEGRMDP	Mouse IgG2a (Glu98-Lys330)
  N-terminus		C-terminus

• Accession #: Q80ZE3.1
• N-terminal Sequence: Met19
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 86 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 102-114 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse Siglec-G Fc Chimera Protein, CF

• PRO940;Sialic acid-binding Ig-like lectin 10;SIGLEC10;SIGLEC-10;SLG2
• Siglec-10
• SiglecG
• Siglec-G

Background

Siglecs are type I transmembrane proteins that belong to the immunoglobulin (Ig) superfamily and function as mammalian lectins (1). They are characterized by an extracellular domain consisting of various numbers of Ig domains with a conserved N-terminal V-set Ig ligand-binding domain. This binds species-specific sialic acid motifs on protein and lipid scaffolds to regulate intracellular signaling pathways (2). The cytoplasmic tail has signaling motifs, in most cases immunoreceptor tyrosine-based inhibitory motif (ITIM) (3). Siglec-G is a member of the CD33-related Siglec family in the mouse. It is the apparent ortholog of human Siglec-10 (4). It is expressed by mature B cells, but significant levels of transcript were also detected in DC, myeloid cells, and to a lesser extent, T cells (5). Mature Siglec-G consists of a 526 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane segment, and a 124 aa cytoplasmic domain. Within the ECD, mouse Siglec-G shares 63% and 86% aa sequence identity with the human and rat ortholog Siglec-10, respectively. Siglec-10 binds sialated proteins and lipids in alpha 2,3 or alpha 2,6 linkage and shows a preference for GT1b gangliosides (6, 7). This binding can be modulated by cis interactions of Siglec-10 with sialated molecules expressed on the same cell (6). When tyrosine phosphorylated, the cytoplasmic ITIMs interact with phosphatases SHP-1 and SHP-2 to propagate inhibitory signals (8, 9).

1. Crocker, P.R. et al. (2007) Nat. Rev. Immunol. 7:255.
2. Poe, J.C. and T.F. Tedder (2012) Trends Immunol. 33:413.
3. Meyer, S.J. et al. (2018) Front. Immunol. 9:2820.
4. Angata, T. et al. (2001) J. Biol. Chem. 276:45128.
5. Chen, G-Y, et al. (2014) Glycobiology 24:800.
6. Li, N. et al. (2001) J. Biol. Chem. 276:28106
7. Rapoport, E. et al. (2003) Bioorg. Med. Chem. Lett. 13:675.
8. Whitney, G. et al. (2001) Eur. J. Biochem. 268:6083.
9. Kitzig, F. et al. (2002) Biochem. Biophys. Res. Commun. 296:355.

Publications for Siglec-G (10103-SL)(1)

Publication using 10103-SL

• Zhang, W;Zeng, Y;Xiao, Q;Wu, Y;Liu, J;Wang, H;Luo, Y;Zhan, J;Liao, N;Cai, Y; An in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses Nature communications 2024-07-06 [PMID: 38971872] (Flow Cytometry, Human)

Bioinformatics

• Uniprot:
  • Q80ZE3.1()